Tyloxapol
 | |
| Systematic (IUPAC) name | |
|---|---|
|
formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
| CAS Number |
25301-02-4  |
| ATC code | R05CA01 |
| PubChem | CID 71388 |
| DrugBank |
DB06439  |
| ChemSpider |
11052515 |
| UNII |
Y27PUL9H56 |
| KEGG |
D03261 |
| ChEMBL |
CHEMBL1201548 |
| Chemical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
| (what is this?) (verify) | |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.
With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]
Tyloxapol is the main active ingredient of the medical device Tacholiquin®. Tacholiquin® is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are: Exosurf, Alevaire
References
- ↑ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association 86 (1): 46–52. PMC 2607653. PMID 8151722.
- ↑ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.
- ↑ Drugs.com: Tyloxapol definition
- ↑ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.
| ||||||||||||||||||||